担当区分：責任著者   掲載種別：研究論文（学術雑誌）  

DOI： 10.1016/j.gore.2025.101979

researchmap

担当区分：責任著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND: Pembrolizumab, an immune checkpoint inhibitor (ICI), has revolutionized the treatment of recurrent cervical cancer; however, its benefits are limited. This study investigated whether peripheral lymphocyte count (PLC) is a prognostic factor for ICI in patients with advanced or recurrent cervical cancer. METHODS: This retrospective study included 47 patients diagnosed with advanced or recurrent cervical cancer, who were treated with pembrolizumab at our hospital between September 2022 and December 2024. The primary outcome was progression-free survival (PFS). The PLC was measured using a blood test conducted immediately before the first administration of pembrolizumab. The optimal PLC cut-off value was determined by using the first quartile point of the PLC distribution. Based on this cut-off value, the patients were allocated into two groups: a normal PLC group (PLChigh) and low PLC group (PLClow). The impact of PLC on PFS was assessed using a Cox proportional hazards regression model using inverse probability of treatment weighting method based on the propensity score, as well as the log-rank test. RESULTS: The median age of the participants was 55 years (interquartile range, 34–84 years). The most common histological type was squamous cell carcinoma (60% of cases). The cut-off value for PLC was set at 710/µL based on the first quartile point. Twelve patients had PLClow (26%) and 35 had PLChigh (74%). Low PLC was significantly associated with shorter PFS (hazard ratio [HR], 2.91, 95% confidence interval [CI], 1.23–6.91, p = 0.013). In the sensitivity analysis, low PLC was also significantly associated with shorter PFS (HR, 4.10; 95% CI, 1.81–9.29, p < 0.001). CONCLUSIONS: PLC may have potential as a prognostic marker for immunochemotherapy in patients with advanced or recurrent cervical cancer. Pre-treatment assessment of PLC could be helpful in identifying patients at risk of poor outcomes and in supporting clinical decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-025-15173-x.

DOI： 10.1186/s12885-025-15173-x

PubMed

researchmap

担当区分：筆頭著者   掲載種別：研究論文（学術雑誌）  

DOI： 10.1016/j.ijgc.2025.102108

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

BACKGROUND & AIMS: Low muscle mass is associated with poor immune checkpoint inhibitor (ICI) efficacy in patients with melanoma; however, whether this is true in all populations remains to be explored. The current study aimed to investigate the effect of low muscle mass on overall survival (OS) and progression-free survival (PFS) of patients with advanced melanoma treated with ICI. METHODS: muscle index (SMI) at the third lumbar spine was calculated from computed tomography (CT) images, and SMI values < 42 cm2/m2 for men and <38 cm2/m2 for women diagnosed low muscle mass. The association of low muscle mass, OS, and PFS with ICI treatment in patients was investigated. RESULTS: Seventy-six patients with advanced melanoma were assessed retrospectively at our institution; 32 were in the low muscle mass group, while 44 were in the normal muscle mass group. The median OS in patients with and without low muscle mass was 7.1 and 26.6 months (hazard ratio [HR] 3.12, 95 % confidence interval [Cl], 1.65-5.89; p < 0.001) and median PFS was 2.1 and 14.8 months, respectively (HR, 3.10; 95 % Cl 1.74-5.54, p < 0.001). Multivariate analysis showed significantly poor differences in OS (HR, 2.46; 95 % CI, 1.20-5.03; p = 0.01) and significant differences in PFS independently in the low muscle mass group (HR, 3.10; 95 % CI, 1.74-5.54; p < 0.001). CONCLUSIONS: Low muscle mass may be a poor prognostic factor for patients with advanced melanoma treated with ICI.

DOI： 10.1016/j.clnesp.2025.02.004

PubMed

researchmap

担当区分：筆頭著者   記述言語：英語   掲載種別：研究論文（学術雑誌）  

OBJECTIVE: The association between sarcopenia and prognosis in patients with platinum-resistant recurrent ovarian cancer remains unclear. This study investigated whether sarcopenia is a prognostic factor in patients with platinum-resistant recurrent ovarian cancer. METHODS: A total of 52 patients diagnosed with platinum-resistant recurrent ovarian cancer who had undergone non-platinum chemotherapy at our institution formed our study population. Body composition and clinicopathological data of these patients were collected retrospectively. Abdominal computed tomography (CT) scans obtained at the time of platinum-resistant recurrent ovarian cancer diagnosis were used to measure the cross-sectional area of skeletal muscles at L3 level. These values were corrected for height to calculate the skeletal muscle index, and accordingly sarcopenia was defined. Overall survival was defined as the primary outcome of the study. The impact of sarcopenia on overall survival was assessed using Cox proportional hazards regression models with inverse probability weighting of treatment based on propensity scores and log-rank tests. RESULTS: The median patient age was 63 years (IQR: 53-71). The most common International Federation of Gynecology and Obstetrics (FIGO) 2018 stage was stage III (50%) and the most common histology was serous or adenocarcinoma (67.3%). The optimal cut-off value of skeletal muscle index was 35.6 cm2/m2, which was calculated using the data of 21 patients with sarcopenia and 31 without sarcopenia. Sarcopenia was significantly associated with shorter overall survival (HR 1.93; 95% CI 1.06-3.49; p=0.03). Subgroup analysis based on patient attributes and prognostic factors suggested a consistent prognostic impact of sarcopenia. Sarcopenia was identified as a significant risk factor, particularly in patients who had higher CA125 levels (HR, 2.47; 95% CI, 1.07 to 5.69; p=0.034) and a higher neutrophil-to-lymphocyte ratio (HR, 2.92; 95% CI, 1.02 to 8.31; p=0.045). CONCLUSION: Sarcopenia significantly shortened the overall survival of patients with platinum-resistant recurrent ovarian cancer.

DOI： 10.1136/ijgc-2024-005323

PubMed

researchmap

記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

researchmap

記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

researchmap

記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

researchmap

記述言語：日本語   出版者・発行元：神奈川産科婦人科学会  

researchmap

記述言語：日本語   出版者・発行元：(一社)関東連合産科婦人科学会  

researchmap

researchmap